I don't know if this has anything to do with Neuralstem but, here it is anyways:
Circuits and Circuit Disorders: Approaches to Neuromodulation: Call for Papers and New Initiative With the American Neurological Association and the Annals of Neurology.
Rosenberg RN1, Feldman EL2.
Maybe, Dr. Feldman can present the ALS data here at:
Spine Summit 2015 - 31st Annual Meeting of the Congress of Neurological Surgeons (CNS)/American Association of Neurological Surgeons (AANS) Section on Disorders of the Spine and Peripheral Nerves
March 4th-7th in Phoenix, Arizona
Brean Capital is a investment bank that focuses mainly on US and China stocks. They were one of the first banks to aggressively expand their coverage into China.
For some reason Garr was unable to attend and speak at this symposium. I wonder if the reason he couldn't attend had anything to do with the Biotech CEO/ Investor meetings?
How long before we get a decision?
I think many here have misunderstood Garr's comments about patients responding differently to the Stem Cell treatment! I think many should go back and listen to the comments carefully and watch the slide show as Garr presented it.
My take is that, they were both talking about the phase 1 ALS trial and how patients that had bulbar ALS didn't respond as well as patients who were treated before they have progressed to Bulbar ALS.
Remember that, Dr. Feldman & Richard Garr haven't talked about Phase 2 ALS results yet!
I agree. I've mentioned in the past what I think a possible partnership would look like. Garr's speech today seems to be painting a picture of CUR having a lot of money to spend on getting a CGMP facility up and running in the USA. Any idea what it would cost to get a CGMP company up & running? Garr has also talked in the past about partnering NSI-189 so Neuralstem could focus more on their Cell Therapy / & now Gene Therapy part of their business.
Garr has stated they would take it to phase 3 if they didn't get the right deal from a potential partner but, maybe, some big pharma co. has realized the huge potential here and made a offer that, Garr couldn't refuse.
Garr has talked many times about partnering NSI-189 for MDD and any other conditions it could possibly treat with another company.
Does this new Phase 1b schizophrenia trial indicate that, they could have struck a deal with a big pharma company?
That's exactly what today's presentation at the BIOTECH/CEO & INVESTOR conference is designed to do!
Garr mentioned that their company (Neuralstem China) has it's own CGMP stem cell manufacturing facility and they are planning to open their own CGMP Stem Cell manufacturing company in the USA in the near future.
Garr has also mentioned during one of his presentations in 2014 that, Neuralstem China is gearing up to start treating 70k stroke patients a year in China with NSI-566.
I think it also means that, the hippocampus is growing ( Neurogenesis) in the phase 1b NSI-189 patients like it has in animal models.
be completed during the 1st q of 2015 and that, the China stroke trial has been accelerated. This is what Garr said during the presentation today. He also said that, the PIVITOL phase 2/3 trial will be starting later this year and is expected to last about two years.
My take is that, this means the 118 patients in the phase 1/2 trial are almost done being treated. It also means that, the results have been very good and the procedure has already been proven to be safe. So, it has received a accelerated rate to treat the patients in the trial.
Just to be clear after reading the Kreg Palko family blogs. Kreg had only the cervical region of his spine injected with 6-8 million Stem Cells. He wasn't able to get the Lumbar region of the Spine treated with Stem Cells yet. Maybe he will be fortunate enough to get the lumbar treatment at a later date.